GEn1E Lifesciences is a platform dedicated to advancing treatments for rare inflammatory diseases. With a focus on devastating diseases that currently lack effective treatment, GEn1E aims to alleviate the suffering of millions of patients and their families while also reducing the enormous costs to society. Their platform pipeline includes a rich array of novel immunomodulators that target a wide range of indications, including pulmonary ARDS, cystic fibrosis, autoimmune conditions like lupus and psoriasis, and neurological disorders such as Alzheimer's and multiple sclerosis.

They have also developed therapies for oncology, acute coronary syndrome, muscle degeneration, and hearing loss, among others. Led by Dr. Ritu Lal, an experienced expert in drug development, GEn1E boasts a team of domain experts and leverages cutting-edge machine learning technology to accelerate drug discovery and development.

Their platform incorporates a curated database, a mapper to match drugs with disease signatures, and a machine learning engine to optimize the entire process. GEn1E is based in Palo Alto, CA, with a laboratory in Mountain View, CA. They welcome collaborations in their mission to cure rare and inflammatory diseases